APPLICATION
Application Note
The peptide is used for blocking the antibody activity of GTX28024. Itusually blocks the antibody activity completely in Western blot by incubating the peptide withequal volume of antibody for 30 min at 37ºC
PROPERTIES
Form
Liquid
Buffer
PBS, 0.1% BSA
Preservative
0.02% Sodium azide
Storage
Store the peptide at -20ºC, stable for one year.
Concentration
0.20 mg/ml (Please refer to the vial label for the specific concentration.)
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
Beta-Secretase 2 , Aeplc , Alp56 , Asp1 , Asp21 , Bae2 , Cda13 , Ceap1 , Drap , Bace2
Background
Accumulation of the abeta in plaques in the cerebral cortex is a critical event in the pathogenesis of Alzheimers disease. Abeta peptide is generated by proteolytic cleavage of the b-amyloid protein precursor(APP) at by secretases. BACE/Asp2 is a novel transmembrane aspartic protease and co-localizes with APP. A BACE homolog was cloned and designated BACE2, Asp1, DRAP (for Down region aspartic protease), and memapsin 1. BACE2 also cleaves APP at b-site and at a different site within Ab. BACE2 locates on chromosome 21q22.3, the so-called Down critical region, suggesting that BACE2 and Ab may also contribute to the pathogenesis of Down syndrome.
Research Area
REFERENCE
There are currently no references for BACE2 peptide (GTX28391). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for BACE2 peptide (GTX28391). Be the first to share your experience with this product.